|
PEX12 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.87492252226684E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.37156993832377E-12 |
| Normal-vs-Stage2 |
1.93603999999459E-05 |
| Normal-vs-Stage3 |
9.43689570931383E-14 |
| Normal-vs-Stage4 |
1.62481139653892E-12 |
| Stage1-vs-Stage2 |
1.251870E-02 |
| Stage1-vs-Stage3 |
6.253500E-02 |
| Stage1-vs-Stage4 |
8.48070000000201E-05 |
| Stage2-vs-Stage3 |
1.015240E-03 |
| Stage2-vs-Stage4 |
3.61469999999864E-05 |
| Stage3-vs-Stage4 |
5.951500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.39617223232835E-13 |
| Normal-vs-AfricanAmerican |
3.60200000049105E-07 |
| Normal-vs-Asian |
8.2885998065052E-10 |
| Caucasian-vs-AfricanAmerican |
8.079600E-01 |
| Caucasian-vs-Asian |
3.431800E-01 |
| AfricanAmerican-vs-Asian |
7.026600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.55111512312578E-16 |
| Normal-vs-Female |
1.88205007134457E-12 |
| Male-vs-Female |
5.669800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.5507373990763E-12 |
| Normal-vs-Age(41-60Yrs) |
2.1094237467878E-15 |
| Normal-vs-Age(61-80Yrs) |
1.48514534004107E-12 |
| Normal-vs-Age(81-100Yrs) |
6.30240000000226E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.733800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.063400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.931600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.551600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.764600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.740000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.39220000000095E-05 |
| Classical-VS-Follicular |
2.159000E-01 |
| Classical-VS-Other |
5.577200E-01 |
| Classical-VS-Normal |
1.51150203464567E-11 |
| Tall-VS-Follicular |
3.9942000000015E-05 |
| Tall-VS-Other |
5.141600E-01 |
| Tall-VS-Normal |
1.62547753035369E-12 |
| Follicular-VS-Other |
3.922400E-01 |
| Follicular-VS-Normal |
1.26139998446462E-09 |
| Other-VS-Normal |
9.596000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.46549439250521E-14 |
| Normal-vs-N1 |
3.77475828372553E-15 |
| N0-vs-N1 |
9.153500E-04 |
|
|
